Covestor LTD Apellis Pharmaceuticals, Inc. Transaction History

Covestor LTD

$181 Million
Q3 2025

A detailed history of Covestor LTD transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Covestor LTD holds 4,088 shares of APLS stock, worth $83,109. This represents 0.05% of its overall portfolio holdings.

Number of Shares

4,088

Previous 4,600 11.13%

Holding current value

$83,109

Previous $80,000 16.25%

% of portfolio

0.05%

Previous 0.05%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Oct 30, 2025	SELL	$17.42 - $28.65 $8,919 - $14,668	-512 Reduced 11.13%	4,088 $93,000
Q2 2025 Aug 11, 2025	BUY	$16.36 - $23.0 $9,897 - $13,915	605 Added 15.14%	4,600 $80,000
Q1 2025 May 12, 2025	BUY	$21.87 - $34.63 $65 - $103	3 Added 0.08%	3,995 $87,000
Q4 2024 Feb 13, 2025	BUY	$26.18 - $35.42 $99,065 - $134,029	3,784 Added 1819.23%	3,992 $127,000
Q3 2024 Nov 01, 2024	BUY	$28.84 - $41.15 $28 - $41	1 Added 0.48%	208 $6,000

Q2 2024 Aug 09, 2024	BUY	$38.07 - $59.71 $38 - $59	1 Added 0.49%	207 $8,000
Q1 2024 May 10, 2024	SELL	$55.39 - $72.47 $55 - $72	-1 Reduced 0.48%	206 $12,000
Q4 2023 Feb 09, 2024	SELL	$37.14 - $64.82 $21,912 - $38,243	-590 Reduced 74.03%	207 $12,000
Q3 2023 Nov 13, 2023	BUY	$23.65 - $89.22 $16,011 - $60,401	677 Added 564.17%	797 $30,000
Q2 2023 Aug 11, 2023	SELL	$76.68 - $93.31 $3,757 - $4,572	-49 Reduced 28.99%	120 $11,000
Q4 2022 Feb 13, 2023	SELL	$43.24 - $61.04 $345 - $488	-8 Reduced 4.52%	169 $8,000
Q3 2022 Nov 14, 2022	SELL	$44.76 - $69.66 $4,386 - $6,826	-98 Reduced 35.64%	177 $12,000
Q2 2022 Aug 10, 2022	SELL	$35.07 - $59.21 $35 - $59	-1 Reduced 0.36%	275 $12,000
Q1 2022 May 13, 2022	BUY	$35.46 - $54.12 $9,113 - $13,908	257 Added 1352.63%	276 $14,000
Q4 2021 Feb 10, 2022	BUY	$30.74 - $49.16 $584 - $934	19 New	19 $1,000

Others Institutions Holding APLS

# of Institutions

329

Shares Held

124M

Call Options Held

4.12M

Put Options Held

756K

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $2.23B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Covestor LTD, based on Form 13F filings with the SEC.

News

Stay updated on Covestor LTD with notifications on news.

Account